Nuvectis Pharma, Inc. (NVCT) stock
NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$19.20+0.09 (+0.47%)
Close on Nov 17, 2026Market cap $625.57MP/E –Yield 0.00%
Nuvectis Pharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Nuvectis Pharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$19.51M. For fiscal 2025 it was -$16.01M. The highest annual figure on record is -$9.50M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$16.01M | – |
| FY2024 | Dec 31, 2024 | -$12.25M | – |
| FY2023 | Dec 31, 2023 | -$15.95M | – |
| FY2022 | Dec 31, 2022 | -$13.56M | – |
| FY2021 | Dec 31, 2021 | -$9.50M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.53M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.97M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.49M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.37M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.17M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.40M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.02M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.36M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.85M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.24M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.08M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.78M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.52M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.42M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.54M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.08M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.43M | – |
See a number that looks wrong?